BRPI0417993A - anticorpo anti-cd52 para tratamento da diabetes - Google Patents

anticorpo anti-cd52 para tratamento da diabetes

Info

Publication number
BRPI0417993A
BRPI0417993A BRPI0417993-5A BRPI0417993A BRPI0417993A BR PI0417993 A BRPI0417993 A BR PI0417993A BR PI0417993 A BRPI0417993 A BR PI0417993A BR PI0417993 A BRPI0417993 A BR PI0417993A
Authority
BR
Brazil
Prior art keywords
antibody
diabetes treatment
treatment
diabetes
campath
Prior art date
Application number
BRPI0417993-5A
Other languages
English (en)
Inventor
Larry E Arthaud
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BRPI0417993A publication Critical patent/BRPI0417993A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"ANTICORPO ANTI-CD52 PARA TRATAMENTO DA DIABETES". A presente invenção refere-se a prevenção e/ou tratamento da diabetes melito do tipo 1, com anticorpos específicos para CD52, por exemplo, CAMPATH-1H.
BRPI0417993-5A 2003-12-22 2004-12-22 anticorpo anti-cd52 para tratamento da diabetes BRPI0417993A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53205903P 2003-12-22 2003-12-22
PCT/US2004/043142 WO2005062893A2 (en) 2003-12-22 2004-12-22 Anti-cd52 antibody treatment for diabetes

Publications (1)

Publication Number Publication Date
BRPI0417993A true BRPI0417993A (pt) 2007-04-27

Family

ID=34738737

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417993-5A BRPI0417993A (pt) 2003-12-22 2004-12-22 anticorpo anti-cd52 para tratamento da diabetes

Country Status (8)

Country Link
US (1) US20070286857A1 (pt)
EP (1) EP1696956A4 (pt)
JP (1) JP2007515492A (pt)
CN (1) CN1956731A (pt)
BR (1) BRPI0417993A (pt)
CA (1) CA2548947A1 (pt)
IL (1) IL176282A0 (pt)
WO (1) WO2005062893A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
WO2014075125A1 (en) 2012-11-15 2014-05-22 The Walter And Eliza Hall Institute Of Medical Research Soluble mediator
EP3456338B1 (en) * 2011-11-15 2020-07-29 The Walter and Eliza Hall Institute of Medical Research Soluble cd52 for use in the treatment or prevention of multiple sclerosis or rheumatoid arthritis
EP2855666B1 (en) 2012-05-25 2019-12-04 Cellectis Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
US11311575B2 (en) * 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
US10449209B2 (en) 2015-04-29 2019-10-22 Arterez, Llc Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin

Also Published As

Publication number Publication date
CA2548947A1 (en) 2005-07-14
JP2007515492A (ja) 2007-06-14
WO2005062893A2 (en) 2005-07-14
WO2005062893A3 (en) 2005-12-29
CN1956731A (zh) 2007-05-02
EP1696956A4 (en) 2007-08-01
IL176282A0 (en) 2006-10-05
US20070286857A1 (en) 2007-12-13
EP1696956A2 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
NZ593289A (en) Anti-neuropilin-1 antibodies for treating angiogenesis
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
TR200200472T2 (tr) Anti-Erb B2 antikorları ile tedavi için dozajlar
BRPI0511008A (pt) agentes de ligação de il-13
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
GEP20125594B (en) Sclerostin binding agents
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
MY143215A (en) Multifocal lenses for pre-presbyopic individuals
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
BE2012C005I2 (pt)
BRPI0606148A2 (pt) anticorpos monoclonais neutralizantes contra a sìndrome respiratória aguda grave associada com o coronavìrus
IL185754A0 (en) Novel anti-plgf antibody
BR0212374A (pt) Oxintomodulina para a prevenção ou para o tratamento do excesso de peso
DK1385864T3 (da) Anti-VEGF-2-antistoffer
BRPI0412265A (pt) uso de calcitonina em osteoartrite
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
BRPI0417993A (pt) anticorpo anti-cd52 para tratamento da diabetes
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper
BRPI0512923A (pt) materiais e métodos para melhorar a saúde, imunidade e crescimento de mariscos
HK1098077A1 (en) Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
EP1642969A4 (en) FLUORESCENCE PROTEIN AND PIGMENT PROTEIN
BRPI0408238A (pt) anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer
BRPI0413204A (pt) terapia de combinação para controle glicêmico
NZ629387A (en) Monoclonal antibodies against amyloid beta protein and uses thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.